Treatment of Human Immunodeficiency Virus—Related Thrombocytopenia With Zidovudine
- John C. Pottage, Jr, MD;
- Constance A. Benson, MD;
- Joel B. Spear, MD;
- Alan L. Landay, PhD;
- Harold A. Kessler, MD
Abstract
Human immunodeficiency virus (HIV)—related thrombocytopenia has been well described and requires therapy in about one half of the patients. Conventional modes of therapy with prednisone, danazol, immunoglobulin, and/or splenectomy have not been uniformly successful. We have administered zidovudine to three patients with HIV-related thrombocytopenia. All three patients responded with a sustained increase in their platelet counts, despite discontinuation of conventional therapy. Interruption of zidovudine therapy was associated with a decrease in platelet count. Concomitant with the elevation in platelet count with zidovudine therapy, there was a reduction in the circulating p24 antigen levels. Whether the elevations in the platelet count in these patients with HIV-related thrombocytopenia is due to the antiviral effect of zidovudine is unknown. It is clear that further studies examining the prospective use of zidovudine in the treatment of HIV-related thrombocytopenia are indicated.
(JAMA 1988;260:3045-3048)
Footnotes
-
Reprint requests to the Section of Infectious Disease, Rush-Presbyterian—St Luke's Medical Center, 1653 W Congress Parkway, Chicago, IL 60612 (Dr Pottage).
